Amgen Inc. $AMGN Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 5.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,332 shares of the medical research company’s stock after selling 5,950 shares during the period. TD Waterhouse Canada Inc.’s holdings in Amgen were worth $38,932,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AMGN. MW Advisory LLC bought a new stake in shares of Amgen during the second quarter worth $1,054,000. Baird Financial Group Inc. boosted its holdings in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares during the last quarter. Integrated Advisors Network LLC boosted its holdings in Amgen by 50.5% in the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after acquiring an additional 6,356 shares during the last quarter. KBC Group NV boosted its holdings in Amgen by 51.7% in the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock valued at $138,574,000 after acquiring an additional 130,497 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new stake in Amgen in the second quarter worth about $3,329,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Barclays boosted their price objective on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Robert W. Baird upped their target price on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Citigroup raised their target price on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada lifted their price target on shares of Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Finally, Scotiabank lifted their price target on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $387.93.

Amgen Price Performance

Amgen stock opened at $432.49 on Friday. The firm has a market capitalization of $233.82 billion, a P/E ratio of 26.88, a PEG ratio of 3.17 and a beta of 0.41. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The business has a 50-day moving average of $415.54 and a 200-day moving average of $374.76. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s payout ratio is currently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.